Abstract
Background: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD).
Objective: The present article aims at systematically reviewing findings of the published and unpublished research on the pharmacological properties, efficacy, safety and tolerability of oral VRX in the treatment of MDD.
Method: A systematic review, in accordance with the Cochrane Collaboration and the PRISMA guidelines, was conducted searching the electronic databases MEDLINE, by combining the following keyterms: ((vortioxetine OR LU AA21004 OR brintellix) AND (antidepressant OR depression OR major depressive disorder), without language/time restrictions. Further studies were retrieved from reference listing of relevant articles or manual search. Preclinical and clinical studies (RCT and open label trials) were here retrieved.
Results: Several placebo-controlled and active-treatment studies demonstrated the antidepressant efficacy and tolerability of VRX in adult patients affected with MDD. In addition, VRX seems to own procognitive activity. VRX seems generally well tolerated, without significant cardiovascular or weight gain effects. The most common adverse events reported included nausea, vomiting, hyperhidrosis, headache, dizziness, somnolence, diarrhoea and dry mouth.
Conclusion: Overall, placebo controlled and active treatment trials support that VRX is effective and well tolerated in MDD. Its combined serotonin reuptake inhibition with agonism, partial agonism and antagonism of a number of receptors might provide a broader spectrum of antidepressant activity than currently available agents.
Keywords: Antidepressant, brintellix, depression, Lu AA21004, major depressive disorder, multimodal, vortioxetine.
CNS & Neurological Disorders - Drug Targets
Title:Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine
Volume: 16 Issue: 1
Author(s): Federica Vellante, Domenico De Berardis, Massimo Di Giannantonio, Andrea de Bartolomeis, Alessandro Carano, Marco Di Nicola, Giampaolo Perna, Roberta Vecchiotti, Ilaria Matarazzo, Laura Orsolini, Giovanni Martinotti, Annastasia L.C. Fiengo, Michele Fornaro, Elisabetta Filomena Buonaguro, Felice Iasevoli, Alessandro Valchera and Carmine Tomasetti
Affiliation:
Keywords: Antidepressant, brintellix, depression, Lu AA21004, major depressive disorder, multimodal, vortioxetine.
Abstract: Background: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD).
Objective: The present article aims at systematically reviewing findings of the published and unpublished research on the pharmacological properties, efficacy, safety and tolerability of oral VRX in the treatment of MDD.
Method: A systematic review, in accordance with the Cochrane Collaboration and the PRISMA guidelines, was conducted searching the electronic databases MEDLINE, by combining the following keyterms: ((vortioxetine OR LU AA21004 OR brintellix) AND (antidepressant OR depression OR major depressive disorder), without language/time restrictions. Further studies were retrieved from reference listing of relevant articles or manual search. Preclinical and clinical studies (RCT and open label trials) were here retrieved.
Results: Several placebo-controlled and active-treatment studies demonstrated the antidepressant efficacy and tolerability of VRX in adult patients affected with MDD. In addition, VRX seems to own procognitive activity. VRX seems generally well tolerated, without significant cardiovascular or weight gain effects. The most common adverse events reported included nausea, vomiting, hyperhidrosis, headache, dizziness, somnolence, diarrhoea and dry mouth.
Conclusion: Overall, placebo controlled and active treatment trials support that VRX is effective and well tolerated in MDD. Its combined serotonin reuptake inhibition with agonism, partial agonism and antagonism of a number of receptors might provide a broader spectrum of antidepressant activity than currently available agents.
Export Options
About this article
Cite this article as:
Vellante Federica, De Berardis Domenico, Di Giannantonio Massimo, de Bartolomeis Andrea, Carano Alessandro, Di Nicola Marco, Perna Giampaolo, Vecchiotti Roberta, Matarazzo Ilaria, Orsolini Laura, Martinotti Giovanni, Fiengo L.C. Annastasia, Fornaro Michele, Buonaguro Filomena Elisabetta, Iasevoli Felice, Valchera Alessandro and Tomasetti Carmine, Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine, CNS & Neurological Disorders - Drug Targets 2017; 16 (1) . https://dx.doi.org/10.2174/1871527315666161025140111
DOI https://dx.doi.org/10.2174/1871527315666161025140111 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation
Current Cardiology Reviews Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Does Pharmacological Therapy Still Play a Role in Preventing Sudden Death in Surgically Treated Tetralogy of Fallot?
Mini-Reviews in Medicinal Chemistry The Role of Natural Killer T Cells in Atherosclerosis
Current Immunology Reviews (Discontinued) The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews Vascular Dysfunction in Aging: Potential Effects of Resveratrol, an Anti- Inflammatory Phytoestrogen
Current Medicinal Chemistry The Role of EC-IC Bypass in Critical Cerebral Hemodynamics of Different Origin
Current Hypertension Reviews Editorial (Thematic Issue: Aging and Metabolic Syndrome: Common Molecular Pathways)
Current Diabetes Reviews How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism